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CONCLUSIONS: The translation evidence tracking tool is a unique device enabling
researchers to submit a consistent and comprehensive translation dossier for FDA
review.
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OBJECTIVES:As the use of existing translated clinical outcome assessments (COAs)
across studies is common and continues to increase, appropriate documentation
of the translation and linguistic validation processes utilized to create target lan-
guage versions is essential.METHODS:A review of the contents of final reports and
certifications for previously completed COA translations was conducted. Addi-
tional discussions with sponsors and CROs regarding final reports, and the preva-
lence of final report deliveries from linguistic validation providers across the in-
dustry were completed. RESULTS: Final reports for linguistic validation are not
provided consistently across the industry. While some companies provide a final
report for every project, upon further discussion with sponsors within the industry
it was revealed that some companies do not automatically generate reports or
provide them to sponsors upon completion of the linguistic validation process.
Based upon regulatory expectations for review of translated COAs, it is recom-
mended to utilize a final report which summarizes the overall linguistic validation
project. This report should document the process used in detail, the reasoning for
linguistic decisions at each stage, evidence of cognitive interviewing, cognitive
interviewing population, demographic information of the respondents, a summary
of the findings, the final formatted version of the questionnaire, and the relevant
certification.CONCLUSIONS: Final reports for COA language versions provide valu-
able information needed to make critical decisions regarding the use of existing
translations. Linguistic validation reports should be structured as a complete pack-
age addressing each item regulatory authorities require for review of translations,
so the sponsor may easily include this in their submission packages. Final reports
should be provided for every COA language version to document the translation
and linguistic validation process completed.
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OBJECTIVES: To determine the best response sets for use in Patient Reported Outcomes
(PRO) instruments intended for translation and subsequent data collection in multina-
tional clinical trials, and to make recommendations for response options to avoid. As
sound response sets are essential for data collection, a high degree of translatability is
vital.METHODS: Twelve response sets from previously translated PRO instruments
were analyzed. Additionally, linguists provided their feedback on translatability of
the response sets. Observed response sets included measures of patient treatment
satisfaction, improvement, discomfort level, frequency of symptoms or adverse
affects and agreement level with statements about treatment or condition.
RESULTS:A response set constructed of “Strongly agree, agree, uncertain, disagree,
strongly disagree” was conceptually equivalent to the source in 94% of observed
back-translations. In comparison, response options including the phrase “. . .of the
time” were conceptually equivalent in 42% of back-translations. The concept of
“fair” was conceptually equivalent in 64% of back-translations and was found to
have negative interpretations in some languages, such as “Weniger gut” (“not so
good”) in German, and positive in others, such as “Elfogadható” (“acceptable”) in
Hungarian. Some response options within response sets may be indistinguishable
when translated, such as “a little bit” and “somewhat.” Furthermore, “bit” is a
non-existent concept in languages other than English. CONCLUSIONS: Response
sets in PROs should achieve equivalence across languages, with no overlap between op-
tions. The aforementioned agreement set is easily localized, and is thus recommended.
Use of verbose terminology and concepts which are non-existent in other languages
should also be avoided. A translatability assessment of response sets is recommended
during instrument development. Where appropriate the use of numerical rating scales or
visual analogue scales is recommended. Such response sets avoid concept overlap, and
numerical results avoid translatability issues.
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HOW MIGHT EXPERIENCE-BASED UTILITY MEASURES INFLUENCE
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OBJECTIVES: The measurement of the ‘quality’ part of the QALY used to assess
health interventions is conventionally based upon the general publics’ preferences
for different health states. Research from behavioural economics tells us that the
elicitation of preferences to inform this analysis introduces a number of biases into
the estimation of the utility generated by technologies. In response to this, various
authors have considered the theoretical possibility of replacing the preference-
based approaches with experience-based estimates of health related utility gains.
This paper compares the ICERs for a range of interventions estimated based on
both preference-based and experience-based valuation techniques. METHODS:
Tariffs associated with changes in health states were extracted from published
data. Tariffs based on four methods were identified: TTO, standard gamble, life
satisfaction, and day affect. These data were combined with estimates of the cost
and effect of a range of interventions to model the impact on ICERs of these alter-
native tariffs, how this varied with intervention type and tariff method, and the
challenges of adopting alternative tariffs. RESULTS: Experience-based utility mea-
sures generate lower ICERs for interventions that generated improvements in the
social and mental dimensions of health outcomes, and higher ICERs for those that
target the pain dimensions of health outcomes. This trend is not, however, repli-
cated across different experience-based utility measures. CONCLUSIONS: Experi-
ence-based utility represents an alternative to the preference-based utility mea-
sures conventionally employed within health economics. If optimal use is to be
made of health care budgets, further work is required to understand why different
utility measures produce different ICERs, and further debate is required to inform
the appropriate basis for reimbursement decisions.
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OBJECTIVES: Rheumatoid Arthritis (RA) is a chronic autoimmune disease, affecting
over 2.9 million adults in Europe. A challenge for new RA therapies is demonstrat-
ing added value not only in efficacy and tolerability but also in terms of overall
benefit for patients, carers, health care systems and society. The aims of this study
were to document current unmet needs in RA in terms of patient-reported and
economic burden and how such concepts may be assessed to capture the value of
RA treatments. METHODS: Articles were identified via searches in MEDLINE, EM-
BASE, EconLit, HEED, CRD databases and PSYCINFO using pre-defined search terms
and limits. PRO measures were identified via the reviewed literature and the Pa-
tient-Reported Outcome and Quality of Life Database (PROQOLID) and were as-
sessed in context of FDA guidelines. RESULTS: The literature search revealed 2,517
abstracts of which 123 articles were reviewed in full. RA symptoms significantly
impact patient’s physical functioning, daily activities, and ability to work. Financial
stability of patients and caregivers is affected and direct and indirect costs are
incurred by health care systems. A conceptual model summarising patient-re-
ported and economic burden of RA was developed to identify key measurement
concepts which can demonstrate efficacy, tolerability, and wider impact of RA
treatments. Relevant endpoint measures were identified; beyond traditional symp-
tom reports the assessment of health-related quality of life, sleep, fatigue, daily
activities, resource use and work productivity can provide data for regulatory, re-
imbursement, patient, and physician decision making. CONCLUSIONS: A patient-
focused approach is increasingly advocated for underpinning individual and soci-
etal health care decisions. PRO measures, therefore, are essential for monitoring
treatment outcomes among RA patients both in clinical trials and clinical practice.
Where adequate instruments are included in clinical trials there exists opportunity
to demonstrate the overall efficacy, tolerability, and value of a treatment to key
stakeholders including regulatory and HTA bodies.
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OBJECTIVES: When developing a new PRO for use in multinational studies it is
recommended that a translatability assurance step is conducted before finalization
and its subsequent translation and linguistic validation. A review of translatability
and subsequent adaptation can reduce the chances of encountering difficulties
related to concepts, idiomatic expressions, response scales, or syntax once trans-
lation has started. This step helps identify potential issues and develop solutions
that side-step potential problems in the later translation process. The aim of this
study was to assess the nature of issues that translatability highlights. METHODS:
Translatability is assessed by native speakers representing several language
groups (e.g. Europe, Africa, Asia, and Latin America). The linguists are asked to
identify possible grammatical, lexical and cultural issues. Their recommendations
are compiled and discussed with the developer of the measure, which is then
adapted in accordance with these findings. The results of translatability checks
were reviewed to find common issues that the process illuminates. RESULTS:
Changes made to a PRO as a direct result of a translatability step can be varied but
all work towards clarity of concepts and expression. Common changes are: 1) Com-
plex sentences are segmented for clarity; 2) Ambiguity is removed; 3) Constructs
common in English but not in other languages are changed; 4) Colloquialisms are
simplified; 5) Elaborations are added to clarify concepts; and 6) Unnecessary noun
repetition is removed. CONCLUSIONS: The translatability assurance step can in-
crease cross-cultural equivalence between original and translated documents, and
tackle potential translation difficulties uniformly before translation begins. It is
recommended as a step in all PRO development projects.
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REGRESSION METHODS FOR HEALTH-RELATED QUALITY OF LIFE DATA IN
LONGITUDINAL SETTINGS: ARE MORE ADVANCED TECHNIQUES REALLY
PERFORMING BETTER?
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OBJECTIVES: The statistical analysis of health utilities and health-related quality
of life (HRQL) scores poses various challenges due to the distributional properties
such data commonly exhibit. These include skewness and heteroscedasticity
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